Olympic Ophthalmics gets FDA clearance for iTEAR100 Neurostimulator

US medical technology company Olympic Ophthalmics has secured clearance from the US Food and Drug Administration for its iTEAR100 Neurostimulator.

iTEAR100 is an external neurostimulator which has been granted a De Novo request by the FDA to temporarily increase acute tear production in adults by stimulating a cutaneous nerve.

Dr Cynthia Matossian, an investigator in the clinical studies and Medical Director at Matossian Eye Associates said: “This novel device is easy and intuitive to use by patients. It produces tears within seconds after gently touching it to the outside of the nose and pressing the ‘on’ button”.

The iTEAR Neurostimulator is a pocket-size device that stimulates the trigeminal nerve with the application to the skin on the external nasal region for around 30 seconds or less. The stimulation of the trigeminal nerve leads to the activation of the parasympathetic nerve pathway that controls tear film homeostasis.

The external neurostimulator has been found to be well-tolerated and effective in clinical trials in temporarily increasing acute tear production.

Olympic Ophthalmics gets FDA clearance for iTEAR100 Neurostimulator. Photo courtesy of Free-Photos from Pixabay.

According to Olympic Ophthalmics, the FDA approved the iTEAR100 Neurostimulator based on the findings of a couple of clinical studies. Included in these are a double-masked, randomized, sham-controlled multi-center study and a multi-center single-arm study in which subjects used the stimulator two times a day.

Dr Michael Gertner – Olympic Ophthalmics Founder and CEO said: “Olympic Ophthalmics is a team of entrepreneurs, clinicians, and investors with deep expertise in ophthalmology, neuromodulation, and medical devices, brought together to develop devices to lower treatment costs and provide high value therapies for ophthalmic diseases.

“FDA clearance is an exciting milestone for our team and more importantly, for patients. It is just the beginning of a new class of neuromodulation technologies in eye care.”

Related posts

• OliX Pharmaceuticals seeks FDA nod for phase 2a trial of OLX10010 (0)
• Rocket Pharmaceuticals gets FDA fast track status for RP-L401 in infantile malignant osteopetrosis (0)
• Janssen, Amgen secure FDA approval for DKd regiment in multiple myeloma (0)
• Kazia Therapeutics gets fast track status for paxalisib in glioblastoma (0)
• Novartis bags Kesimpta FDA approval for relapsing forms of MS (0)
• Kazia Therapeutics gets US RPDD for paxalisib in childhood brain cancer (0)
• Bayer gets Lampit FDA approval for Chagas disease in pediatric patients (0)
• Farxiga : AstraZeneca gets FDA fast track status for heart failure after MI (0)
• Ascentage Pharma gets FDA ODD for APG-2575 in Waldenström macroglobulinemia (0)
• CenterLab’s anti-diabetic drug candidate CS02 meets primary endpoint in phase 2 trial (0)